BUENOS ARIES, Argentina, Dec. 6,
2018 /PRNewswire/ -- Janne
Huhtala, CEO of MEGIN, a manufacturer of
magnetoencephalography (MEG) technology for functional brain
imaging, spoke about the future innovation of MEG technology during
the Fifth Annual G20 World Brain Mapping Summit/Neuroscience
20.
The N20, held on November 26-27,
in Buenos Aries, Argentina, brought together leading
specialists, directors of International Brain Initiatives and
medical associations presidents, to discuss the global economic
impact of neurological disorders and build greater collaboration in
fields related to epilepsy, mental health, neuro-oncology,
neurotrauma, spine and neurosurgery. N20 leaders published
resolution 27112018 with consensus recommendations that will
address the economic burden of brain, spine and other nervous
system disorders that amount to over $13
Trillion USD annually by introducing game-changing
diagnostics and therapeutics such as MEG.
During the N20 summit, Huhtala addressed how the use of
functional brain imaging with MEG has impacted patient care and led
to translational research of challenging neurological conditions.
He explained that through understanding brain connectivity, there
is the potential for the clinical community to develop new methods
of improving the diagnosis, treatment and rehabilitation of
diseases.
"It was an honor to present to a room of esteemed leaders in
neuroscience community from around the world," said Huhtala. "The
focus of the conference aligns with our corporate goals of
innovating MEG technology and we look forward to supporting the
clinical community in search of ways to better understand how the
brain is connected."
"MEG is a great technology that has been neglected for years,"
said Dr. Babak Kateb, Global
President and Chairman of Neuroscience-20 (N20), Chairman of the
board and CEO of Society for Brain Mapping and Therapeutics (SBMT),
President of Brain Mapping Foundation, Director of National Center
for NanoBioElectronic (NCNBE) and Director of Brain Technology and
Innovation Park (BTIP).
"Our patients have been deprived access to this technology for
decades. It is refreshing to see MEGIN has a convincing strategic
plan to make this technology as prevalent and accessible as MRI.
This could not have been possible without the visionary leadership
of Mr. Janne Huhtala who has track
record in neurotech innovation, clearly understands the
technology/field and has a passion to help millions of patients
through cutting-edge technology. This is a great example of how N20
could bring advanced therapeutics and diagnostics to the millions
of patients through global collaborations," said Kateb.
About MEGIN
In July 2018, York Instruments, a
subsidiary of Croton Healthcare, acquired MEGIN from Elekta,
forming a neurosciences technology company focused on developing
innovative solutions in functional brain imaging.
Based in Helsinki, Finland,
MEGIN has been the largest provider of MEG technology for
functional brain imaging. TRUIX™ neo, launched in 2018, is the
fourth-generation system introduced for the presurgical evaluation
of epilepsy, brain tumors, or other lesions, and surgical planning
for localization of sensory information. With a dynamic view of the
human brain, TRIUX neo is a non-invasive, real time, patient
specific view of neural activity with millimeter accuracy and
millisecond resolution.
For further information, please contact:
For MEGIN:
Tyler
Lecceadone
SeyferthPR
616-776-3511
lecceadone@seyferthpr.com
View original content to download
multimedia:http://www.prnewswire.com/news-releases/megin-ceo-janne-huhtala-speaks-at-neuroscience-20-n20g20-world-brain-mapping-summit-300761552.html
SOURCE MEGIN